What is Gurudarshan Khalsa's specialty?

Gurudarshan Khalsa (NPI 1356409973) is a Medicare-billing provider whose primary specialty is Family Practice in Ferndale, MI.

Where does Gurudarshan Khalsa practice?

Gurudarshan Khalsa practices in Ferndale, MI, based on the location reported in the CMS Medicare provider datasets for NPI 1356409973.

How much does Medicare pay Gurudarshan Khalsa?

Gurudarshan Khalsa (NPI 1356409973) received approximately $657 in total Medicare Part B payments, serving 16 beneficiaries, per the CMS Medicare Physician & Other Practitioners dataset.

PROVIDER PROFILE · NPI 1356409973

Gurudarshan KhalsaM.D.

Family PracticeFerndale, MII

MEDICARE UTILIZATION · PART B · 2024

No data available for this provider in 2024.

PRESCRIBING · PART D · 2024

Total Rx claims

Beneficiaries

—

Total drug cost

$1K

Distinct drugs

Brand share

100.0%

Top prescribed drugs

Buprenorphine Hcl/Naloxone Hcl13 claims

QUALITY · MIPS · 2024

No data available for this provider in 2024.

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

No data available for this provider in 2024.

REFERRAL NETWORK

Where Gurudarshan Khalsa's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 1 inbound referrers · 2 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
UNITED INDIAN HEALTH SERVICES, INC.	19	53

Refers patients to

Outbound — where patients go next

Physician	Patients	Visits
UNITED INDIAN HEALTH SERVICES, INC.	50	156
Laboratory Corporation Of America Clinical Laboratory · San Diego, CA	23	74

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history